艾蘆庫單抗

艾蘆庫單抗（INN：Icrucumab；開發代號：IMC-18F1）是一種人單株抗體，設計用於治療實體瘤。^[1]^[2]艾蘆庫單抗由ImClone Systems（英語：ImClone Systems）公司開發，正在進行I期試驗。^[3]

參考資料

^ Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab (PDF). American Medical Association. [2024-01-21]. （原始內容存檔 (PDF)於2012-09-28）.
^ LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. April 2014, 32 (2): 303–11. PMID 23903897. S2CID 34756277. doi:10.1007/s10637-013-9998-8.
^ Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov